Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Stephan Wienert is active.

Publication


Featured researches published by Stephan Wienert.


Annals of Oncology | 2015

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

Roberto Salgado; Carsten Denkert; Sandra Demaria; Nicolas Sirtaine; Frederick Klauschen; Giancarlo Pruneri; Stephan Wienert; G. Van den Eynden; F. L. Baehner; Frédérique Penault-Llorca; Edith A. Perez; E. A. Thompson; W. F. Symmans; Andrea L. Richardson; Jane E. Brock; Carmen Criscitiello; H. Bailey; Michail Ignatiadis; G. Floris; Joseph A. Sparano; Zuzana Kos; Torsten O. Nielsen; David L. Rimm; Kimberly H. Allison; Jorge S. Reis-Filho; Sibylle Loibl; Christos Sotiriou; Giuseppe Viale; Sunil Badve; Sylvia Adams

BACKGROUND The morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer (BC) is gaining momentum as evidence strengthens for the clinical relevance of this immunological biomarker. Accumulating evidence suggests that the extent of lymphocytic infiltration in tumor tissue can be assessed as a major parameter by evaluation of hematoxylin and eosin (H&E)-stained tumor sections. TILs have been shown to provide prognostic and potentially predictive value, particularly in triple-negative and human epidermal growth factor receptor 2-overexpressing BC. DESIGN A standardized methodology for evaluating TILs is now needed as a prerequisite for integrating this parameter in standard histopathological practice, in a research setting as well as in clinical trials. This article reviews current data on the clinical validity and utility of TILs in BC in an effort to foster better knowledge and insight in this rapidly evolving field, and to develop a standardized methodology for visual assessment on H&E sections, acknowledging the future potential of molecular/multiplexed approaches. CONCLUSIONS The methodology provided is sufficiently detailed to offer a uniformly applied, pragmatic starting point and improve consistency and reproducibility in the measurement of TILs for future studies.


Journal of Clinical Oncology | 2015

Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers

Carsten Denkert; Gunter von Minckwitz; Jan C. Brase; Bruno V. Sinn; Stephan Gade; Ralf Kronenwett; Berit M. Pfitzner; Christoph Salat; Sherene Loi; Wolfgang D. Schmitt; Christian Schem; Karin Fisch; Silvia Darb-Esfahani; Keyur Mehta; Christos Sotiriou; Stephan Wienert; P Klare; Fabrice Andre; Frederick Klauschen; Jens-Uwe Blohmer; Kristin Krappmann; Marcus Schmidt; Hans Tesch; Sherko Kümmel; Peter Sinn; Christian Jackisch; Manfred Dietel; Toralf Reimer; Michael Untch; Sibylle Loibl

PURPOSE Modulation of immunologic interactions in cancer tissue is a promising therapeutic strategy. To investigate the immunogenicity of human epidermal growth factor receptor 2 (HER2) -positive and triple-negative (TN) breast cancers (BCs), we evaluated tumor-infiltrating lymphocytes (TILs) and immunologically relevant genes in the neoadjuvant GeparSixto trial. PATIENTS AND METHODS GeparSixto investigated the effect of adding carboplatin (Cb) to an anthracycline-plus-taxane combination (PM) on pathologic complete response (pCR). A total of 580 tumors were evaluated before random assignment for stromal TILs and lymphocyte-predominant BC (LPBC). mRNA expression of immune-activating (CXCL9, CCL5, CD8A, CD80, CXCL13, IGKC, CD21) as well as immunosuppressive factors (IDO1, PD-1, PD-L1, CTLA4, FOXP3) was measured in 481 tumors. RESULTS Increased levels of stromal TILs predicted pCR in univariable (P < .001) and multivariable analyses (P < .001). pCR rate was 59.9% in LPBC and 33.8% for non-LPBC (P < .001). pCR rates ≥ 75% were observed in patients with LPBC tumors treated with PMCb, with a significant test for interaction with therapy in the complete (P = .002) and HER2-positive (P = .006), but not the TNBC, cohorts. Hierarchic clustering of mRNA markers revealed three immune subtypes with different pCR rates (P < .001). All 12 immune mRNA markers were predictive for increased pCR. The highest odds ratios (ORs) were observed for PD-L1 (OR, 1.57; 95% CI, 1.34 to 1.86; P < .001) and CCL5 (OR, 1.41; 95% CI, 1.23 to 1.62; P < .001). CONCLUSION Immunologic factors were highly significant predictors of therapy response in the GeparSixto trial, particularly in patients treated with Cb. After further standardization, they could be included in histopathologic assessment of BC.


Scientific Reports | 2012

Detection and Segmentation of Cell Nuclei in Virtual Microscopy Images: A Minimum-Model Approach

Stephan Wienert; Daniel Heim; Kai Saeger; Albrecht Stenzinger; Michael Beil; Peter Hufnagl; Manfred Dietel; Carsten Denkert; Frederick Klauschen

Automated image analysis of cells and tissues has been an active research field in medical informatics for decades but has recently attracted increased attention due to developments in computer and microscopy hardware and the awareness that scientific and diagnostic pathology require novel approaches to perform objective quantitative analyses of cellular and tissue specimens. Model-based approaches use a priori information on cell shape features to obtain the segmentation, which may introduce a bias favouring the detection of cell nuclei only with certain properties. In this study we present a novel contour-based “minimum-model” cell detection and segmentation approach that uses minimal a priori information and detects contours independent of their shape. This approach avoids a segmentation bias with respect to shape features and allows for an accurate segmentation (precision = 0.908; recall = 0.859; validation based on ∼8000 manually-labeled cells) of a broad spectrum of normal and disease-related morphological features without the requirement of prior training.


Oncotarget | 2016

Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma

Silvia Darb-Esfahani; Catarina Alisa Kunze; Hagen Kulbe; Jalid Sehouli; Stephan Wienert; Judith Lindner; Jan Budczies; Michael Bockmayr; Manfred Dietel; Carsten Denkert; Ioana Braicu; Korinna Jöhrens

Aims Antibodies targeting the checkpoint molecules programmed cell death 1 (PD-1) and its ligand PD-L1 are emerging cancer therapeutics. We systematically investigated PD-1 and PD-L1 expression patterns in the poor-prognosis tumor entity high-grade serous ovarian carcinoma. Methods PD-1 and PD-L1 protein expression was determined by immunohistochemistry on tissue microarrays from 215 primary cancers both in cancer cells and in tumor-infiltrating lymphocytes (TILs). mRNA expression was measured by quantitative reverse transcription PCR. An in silico validation of mRNA data was performed in The Cancer Genome Atlas (TCGA) dataset. Results PD-1 and PD-L1 expression in cancer cells, CD3+, PD-1+, and PD-L1+ TILs densities as well as PD-1 and PD-L1 mRNA levels were positive prognostic factors for progression-free (PFS) and overall survival (OS), with all factors being significant for PFS (p < 0.035 each), and most being significant for OS. Most factors also had prognostic value that was independent from age, stage, and residual tumor. Moreover, high PD-1+ TILs as well as PD-L1+ TILs densities added prognostic value to CD3+TILs (PD-1+: p = 0.002,; PD-L1+: p = 0.002). The significant positive prognostic impact of PD-1 and PD-L1 mRNA expression could be reproduced in the TCGA gene expression datasets (p = 0.02 and p < 0.0001, respectively). Conclusions Despite their reported immune-modulatory function, high PD-1 and PD-L1 levels are indicators of a favorable prognosis in ovarian cancer. Our data indicate that PD-1 and PD-L1 molecules are biologically relevant regulators of the immune response in high-grade serous ovarian carcinoma, which is an argument for the evaluation of immune checkpoint inhibiting drugs in this tumor entity.


Journal of Experimental Medicine | 2014

Fate mapping reveals origin and dynamics of lymph node follicular dendritic cells

Meryem Jarjour; Audrey Jorquera; Isabelle Mondor; Stephan Wienert; Priyanka Narang; Mark Coles; Frederick Klauschen; Marc Bajénoff

The lymph node follicular dendritic cell (FDC) network is derived from the expansion and differentiation of marginal reticular cells, as are the new FDCs generated during an immune response.


Journal of Experimental Medicine | 2013

Multicolor fate mapping of Langerhans cell homeostasis

Clément Ghigo; Isabelle Mondor; Audrey Jorquera; Jonathan A. Nowak; Stephan Wienert; Sonja Zahner; Bjoern E. Clausen; Hervé Luche; Bernard Malissen; Frederick Klauschen; Marc Bajénoff

The adult epidermal Langerhans cell network is formed by adjacent proliferative units composed of dividing cells and their terminally differentiated daughter cells.


Modern Pathology | 2016

Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer : results of the ring studies of the international immuno-oncology biomarker working group

Carsten Denkert; Stephan Wienert; Audrey Poterie; Sibylle Loibl; Jan Budczies; Sunil Badve; Zsuzsanna Bago-Horvath; Anita Bane; Shahinaz Bedri; Jane E. Brock; Ewa Chmielik; Matthias Christgen; Cecile Colpaert; Sandra Demaria; Gert Van den Eynden; Giuseppe Floris; Stephen B. Fox; Dongxia Gao; Barbara Ingold Heppner; S Rim Kim; Zuzana Kos; Hans Kreipe; Sunil R. Lakhani; Frédérique Penault-Llorca; Giancarlo Pruneri; Nina Radosevic-Robin; David L. Rimm; Stuart J. Schnitt; Bruno V. Sinn; Peter Sinn

Multiple independent studies have shown that tumor-infiltrating lymphocytes (TIL) are prognostic in breast cancer with potential relevance for response to immune-checkpoint inhibitor therapy. Although many groups are currently evaluating TIL, there is no standardized system for diagnostic applications. This study reports the results of two ring studies investigating TIL conducted by the International Working Group on Immuno-oncology Biomarkers. The study aim was to determine the intraclass correlation coefficient (ICC) for evaluation of TIL by different pathologists. A total of 120 slides were evaluated by a large group of pathologists with a web-based system in ring study 1 and a more advanced software-system in ring study 2 that included an integrated feedback with standardized reference images. The predefined aim for successful ring studies 1 and 2 was an ICC above 0.7 (lower limit of 95% confidence interval (CI)). In ring study 1 the prespecified endpoint was not reached (ICC: 0.70; 95% CI: 0.62–0.78). On the basis of an analysis of sources of variation, we developed a more advanced digital image evaluation system for ring study 2, which improved the ICC to 0.89 (95% CI: 0.85–0.92). The Fleiss’ kappa value for <60 vs ≥60% TIL improved from 0.45 (ring study 1) to 0.63 in RS2 and the mean concordance improved from 88 to 92%. This large international standardization project shows that reproducible evaluation of TIL is feasible in breast cancer. This opens the way for standardized reporting of tumor immunological parameters in clinical studies and diagnostic practice. The software-guided image evaluation approach used in ring study 2 may be of value as a tool for evaluation of TIL in clinical trials and diagnostic practice. The experience gained from this approach might be applicable to the standardization of other diagnostic parameters in histopathology.


Clinical Cancer Research | 2015

Standardized Ki67 diagnostics using automated scoring - clinical validation in the GeparTrio breast cancer study

Frederick Klauschen; Stephan Wienert; Wolfgang D. Schmitt; Sibylle Loibl; Bernd Gerber; Jens-Uwe Blohmer; Jens Huober; Thomas Rüdiger; Erhard Erbstößer; Keyur Mehta; Bianca Lederer; Manfred Dietel; Carsten Denkert; Gunter von Minckwitz

Purpose: Scoring proliferation through Ki67 immunohistochemistry is an important component in predicting therapy response to chemotherapy in patients with breast cancer. However, recent studies have cast doubt on the reliability of “visual” Ki67 scoring in the multicenter setting, particularly in the lower, yet clinically important, proliferation range. Therefore, an accurate and standardized Ki67 scoring is pivotal both in routine diagnostics and larger multicenter studies. Experimental Design: We validated a novel fully automated Ki67 scoring approach that relies on only minimal a priori knowledge on cell properties and requires no training data for calibration. We applied our approach to 1,082 breast cancer samples from the neoadjuvant GeparTrio trial and compared the performance of automated and manual Ki67 scoring. Results: The three groups of autoKi67 as defined by low (≤15%), medium (15.1%–35%), and high (>35%) automated scores showed pCR rates of 5.8%, 16.9%, and 29.5%, respectively. AutoKi67 was significantly linked to prognosis with overall and progression-free survival P values POS < 0.0001 and PPFS < 0.0002, compared with POS < 0.0005 and PPFS < 0.0001 for manual Ki67 scoring. Moreover, automated Ki67 scoring was an independent prognosticator in the multivariate analysis with POS = 0.002, PPFS = 0.009 (autoKi67) versus POS = 0.007, PPFS = 0.004 (manual Ki67). Conclusions: The computer-assisted Ki67 scoring approach presented here offers a standardized means of tumor cell proliferation assessment in breast cancer that correlated with clinical endpoints and is deployable in routine diagnostics. It may thus help to solve recently reported reliability concerns in Ki67 diagnostics. Clin Cancer Res; 21(16); 3651–7. ©2014 AACR.


Diagnostic Pathology | 2013

CognitionMaster: an object-based image analysis framework

Stephan Wienert; Daniel Heim; Manato Kotani; Björn Lindequist; Albrecht Stenzinger; Masaru Ishii; Peter Hufnagl; Michael Beil; Manfred Dietel; Carsten Denkert; Frederick Klauschen

BackgroundAutomated image analysis methods are becoming more and more important to extract and quantify image features in microscopy-based biomedical studies and several commercial or open-source tools are available. However, most of the approaches rely on pixel-wise operations, a concept that has limitations when high-level object features and relationships between objects are studied and if user-interactivity on the object-level is desired.ResultsIn this paper we present an open-source software that facilitates the analysis of content features and object relationships by using objects as basic processing unit instead of individual pixels. Our approach enables also users without programming knowledge to compose “analysis pipelines“ that exploit the object-level approach. We demonstrate the design and use of example pipelines for the immunohistochemistry-based cell proliferation quantification in breast cancer and two-photon fluorescence microscopy data about bone-osteoclast interaction, which underline the advantages of the object-based concept.ConclusionsWe introduce an open source software system that offers object-based image analysis. The object-based concept allows for a straight-forward development of object-related interactive or fully automated image analysis solutions. The presented software may therefore serve as a basis for various applications in the field of digital image analysis.


Advances in Anatomic Pathology | 2017

Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology Biomarkers Working Group: part 2: TILs in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain Tumors

Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A. Russell; Thomas John; Bibhusal Thapa; Michael Christie; Koen K. Van de Vijver; Monica V. Estrada; Paula I Gonzalez-Ericsson; Melinda E. Sanders; Benjamin Solomon; Cinzia Solinas; Gert G. Van den Eynden; Yves Allory; Matthias Preusser; Johannes A. Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E. A. Thompson; Sunil R. Lakhani; Seong Rim Kim; Stuart J. Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J. Scherer

Assessment of the immune response to tumors is growing in importance as the prognostic implications of this response are increasingly recognized, and as immunotherapies are evaluated and implemented in different tumor types. However, many different approaches can be used to assess and describe the immune response, which limits efforts at implementation as a routine clinical biomarker. In part 1 of this review, we have proposed a standardized methodology to assess tumor-infiltrating lymphocytes (TILs) in solid tumors, based on the International Immuno-Oncology Biomarkers Working Group guidelines for invasive breast carcinoma. In part 2 of this review, we discuss the available evidence for the prognostic and predictive value of TILs in common solid tumors, including carcinomas of the lung, gastrointestinal tract, genitourinary system, gynecologic system, and head and neck, as well as primary brain tumors, mesothelioma and melanoma. The particularities and different emphases in TIL assessment in different tumor types are discussed. The standardized methodology we propose can be adapted to different tumor types and may be used as a standard against which other approaches can be compared. Standardization of TIL assessment will help clinicians, researchers and pathologists to conclusively evaluate the utility of this simple biomarker in the current era of immunotherapy.

Collaboration


Dive into the Stephan Wienert's collaboration.

Top Co-Authors

Avatar

Frederick Klauschen

Humboldt University of Berlin

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Christos Sotiriou

Université libre de Bruxelles

View shared research outputs
Top Co-Authors

Avatar

Harshita Sharma

Technical University of Berlin

View shared research outputs
Researchain Logo
Decentralizing Knowledge